Doctors fret about long-term impact of expensive drugs

The New York Times looks at the growing number of biotech drugs that cost as much as $10,000 per month, often only prolonging patients' lives by a matter of weeks or months. For some cancer specialists, it seems only a matter of time before the use of the super-expensive drugs is rationed. And analysts note that pressure will grow as hundreds of late-stage biotech drugs are approved by the FDA.

- read this article from The New York Times for more

Suggested Articles

The public financing will enable Monopar to start a phase 3 trial of a prophylactic treatment for a side effect of chemoradiotherapy. 

The dispute centers on whether Asa Abeliovich used Alector’s confidential information in connection with his work for Prevail Therapeutics.

GSK poaches Merck KGaA's Martinez-Davis to helm pharma stateside; Bulto named Novartis U.S. pharma head; Allergan's Saunders set for huge parachute.